Phase I/II Clinical Trial Combining TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Latest Information Update: 04 Mar 2022
At a glance
- Drugs Quaratusugene ozeplasmid (Primary) ; Dexamethasone; Dexamethasone; Diphenhydramine; Diphenhydramine; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Genprex
- 11 Feb 2022 Status changed from active, no longer recruiting to discontinued.
- 20 Jul 2020 Planned End Date changed from 1 Jul 2020 to 1 Jun 2021.
- 09 Jan 2019 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.